{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T10:09:59Z","timestamp":1648894199417},"reference-count":5,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med","J. Jpn. Soc. Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/naika.103.2261","type":"journal-article","created":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T18:05:19Z","timestamp":1441821919000},"page":"2261-2268","source":"Crossref","is-referenced-by-count":0,"title":["6. Current Treatment Strategies for Chronic Myelogenous Leukemia"],"prefix":"10.2169","volume":"103","author":[{"given":"Itaru","family":"Matsumura","sequence":"first","affiliation":[{"name":"Department of Hematology and Rheumatology, Kinki University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Druker BJ, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006.","DOI":"10.1056\/NEJMoa062867"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Saglio G, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259, 2010.","DOI":"10.1056\/NEJMoa0912614"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kantarjian H, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010.","DOI":"10.1056\/NEJMoa1002315"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Baccarani M, et al: Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. J Clin Oncol 27: 6041-6051, 2009.","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Baccarani M, et al: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884, 2013.","DOI":"10.1182\/blood-2013-05-501569"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":["6\uff0e\u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u306e\u6cbb\u7642"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/103\/9\/103_2261\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T05:20:55Z","timestamp":1567142455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/103\/9\/103_2261\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.103.2261","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}